FDA Approves Innovative Cream to Treat Chronic Hand Eczema
The FDA has approved the first prescription cream for treating chronic hand eczema, offering new hope to millions affected by this persistent skin condition. Learn about this breakthrough treatment and its potential impact.
The U.S. Food and Drug Administration (FDA) has approved the first topical cream specifically designed to treat chronic hand eczema (CHE), a persistent and often debilitating skin condition. CHE is characterized by redness, itching, cracking, and inflammation on the hands and wrists, affecting about 10% of the U.S. population. Unlike atopic dermatitis, which is more common, CHE tends to be rarer but significantly impacts quality of life, particularly in individuals exposed to irritants or allergens occupationally, such as those working in cleaning, healthcare, or hairstyling industries.
The newly approved medication, Anzupgo (delgocitinib), is intended for adults with moderate-to-severe CHE who cannot or do not respond well to topical steroids. It functions by inhibiting JAK enzymes, which are involved in the inflammatory processes that trigger eczema flare-ups.
This treatment offers hope for many patients, as current options were limited and often ineffective. Studies prior to approval demonstrated that patients using Anzupgo experienced notably improved symptoms compared to placebo. Importantly, the cream does not carry the boxed warnings associated with other JAK inhibitors, making it a safer option.
Experts emphasize the significance of this approval. Dr. Linda Stein Gold from Henry Ford Health expressed optimism, citing the considerable burden CHE imposes on sufferers. Kristin Belleson, CEO of the National Eczema Association, highlighted that this development provides new hope for those whose daily lives are disrupted by the disease.
Internationally, Anzupgo has already been approved in regions including the European Union, United Kingdom, Switzerland, and the United Arab Emirates. Its availability in the U.S. marks a pivotal step in advancing treatment options for chronic hand eczema.
This milestone reflects ongoing efforts to address difficult-to-treat skin conditions and improve patient outcomes, especially for those facing persistent and recurrent symptoms.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
A Neurologist's Perspective on Living with Alzheimer's Disease: Insights and Personal Experience
Dr. Daniel Gibbs shares his personal journey with Alzheimer's disease, highlighting early signs, genetic risk, lifestyle strategies, and the importance of early detection for managing the condition effectively.
Decade-Long Study Finds Stereotactic Body Radiation Therapy Matches Surgery Outcomes for Early-Stage Lung Cancer
A 10-year study shows stereotactic body radiation therapy provides survival outcomes comparable to surgery for early-stage lung cancer, with added quality-of-life benefits, emphasizing its role as a key treatment option.
Harnessing AI to Prevent Millions of Food Poisoning Cases
Discover how artificial intelligence and hyperspectral imaging are transforming food safety by enabling rapid detection of contaminants, potentially preventing up to 600 million cases of food poisoning annually.
Canadian Cannabis Use Slightly Rises While Misuse Declines Post-Legalization
Research shows a slight increase in cannabis use and a decrease in misuse among Canadian adults post-legalization, highlighting the impact of regulatory policies.